| . | ctDNAb . | ctDNAf . | . | ||||
|---|---|---|---|---|---|---|---|
| Characteristic . | negative . | positive . | P-value . | negative . | positive . | P-value . | Total . |
| n | 38 | 113 | 61 | 90 | 151 | ||
| Age | 0.13 | 0.18 | |||||
| Mean ± SD | 60.7 ± 9 | 63.8 ± 9.7 | 62.4 ± 9.5 | 63.5 ± 9.7 | 63.1 ± 9.6 | ||
| < 65 y | 23 (61%) | 51 (45%) | 34 (56%) | 40 (44%) | 74 (49%) | ||
| ≥ 65 y | 15 (39%) | 62 (55%) | 27 (44%) | 50 (56%) | 77 (51%) | ||
| Sex | 0.84 | 0.73 | |||||
| Male | 24 (63%) | 75 (66%) | 39 (64%) | 60 (67%) | 99 (66%) | ||
| Female | 14 (37%) | 38 (34%) | 22 (36%) | 30 (33%) | 52 (34%) | ||
| Performance status | 0.84 | 0.86 | |||||
| ECOG 0 | 22 (59%) | 68 (61%) | 36 (60%) | 54 (61%) | 90 (61%) | ||
| ECOG 1/2 | 15 (41%) | 43 (39%) | 24 (40%) | 34 (39%) | 58 (39%) | ||
| Type of metastasis | 1.00 | 1.00 | |||||
| synchronous | 34 (89%) | 100 (88%) | 54 (89%) | 80 (89%) | 134 (89%) | ||
| metachronous | 4 (11%) | 13 (12%) | 7 (11%) | 10 (11%) | 17 (11%) | ||
| Number of metastatic sites | 0.13 | 0.39 | |||||
| 1 | 20 (53%) | 42 (37%) | 28 (46%) | 34 (38%) | 62 (41%) | ||
| > 1 | 18 (47%) | 71 (63%) | 33 (54%) | 56 (62%) | 89 (59%) | ||
| aCEA (baseline) | 0.0021 | 0.0047 | |||||
| ≤ 20 ng/mL | 21 (62%) | 32 (31%) | 30 (53%) | 23 (28%) | 53 (38%) | ||
| > 20 ng/mL | 13 (38%) | 72 (69%) | 27 (47%) | 58 (72%) | 85 (62%) | ||
| Platelets (baseline) | 0.42 | 0.59 | |||||
| ≤ ULN | 28 (74%) | 73 (65%) | 43 (70%) | 58 (65%) | 101 (67%) | ||
| > ULN | 10 (26%) | 39 (35%) | 18 (30%) | 31 (35%) | 49 (33%) | ||
| Primary tumor location | 0.40 | 0.58 | |||||
| left side | 25 (74%) | 67 (64%) | 38 (69%) | 54 (64%) | 92 (66%) | ||
| right side | 9 (26%) | 38 (36%) | 17 (31%) | 30(36%) | 47(34%) | ||
| . | ctDNAb . | ctDNAf . | . | ||||
|---|---|---|---|---|---|---|---|
| Characteristic . | negative . | positive . | P-value . | negative . | positive . | P-value . | Total . |
| n | 38 | 113 | 61 | 90 | 151 | ||
| Age | 0.13 | 0.18 | |||||
| Mean ± SD | 60.7 ± 9 | 63.8 ± 9.7 | 62.4 ± 9.5 | 63.5 ± 9.7 | 63.1 ± 9.6 | ||
| < 65 y | 23 (61%) | 51 (45%) | 34 (56%) | 40 (44%) | 74 (49%) | ||
| ≥ 65 y | 15 (39%) | 62 (55%) | 27 (44%) | 50 (56%) | 77 (51%) | ||
| Sex | 0.84 | 0.73 | |||||
| Male | 24 (63%) | 75 (66%) | 39 (64%) | 60 (67%) | 99 (66%) | ||
| Female | 14 (37%) | 38 (34%) | 22 (36%) | 30 (33%) | 52 (34%) | ||
| Performance status | 0.84 | 0.86 | |||||
| ECOG 0 | 22 (59%) | 68 (61%) | 36 (60%) | 54 (61%) | 90 (61%) | ||
| ECOG 1/2 | 15 (41%) | 43 (39%) | 24 (40%) | 34 (39%) | 58 (39%) | ||
| Type of metastasis | 1.00 | 1.00 | |||||
| synchronous | 34 (89%) | 100 (88%) | 54 (89%) | 80 (89%) | 134 (89%) | ||
| metachronous | 4 (11%) | 13 (12%) | 7 (11%) | 10 (11%) | 17 (11%) | ||
| Number of metastatic sites | 0.13 | 0.39 | |||||
| 1 | 20 (53%) | 42 (37%) | 28 (46%) | 34 (38%) | 62 (41%) | ||
| > 1 | 18 (47%) | 71 (63%) | 33 (54%) | 56 (62%) | 89 (59%) | ||
| aCEA (baseline) | 0.0021 | 0.0047 | |||||
| ≤ 20 ng/mL | 21 (62%) | 32 (31%) | 30 (53%) | 23 (28%) | 53 (38%) | ||
| > 20 ng/mL | 13 (38%) | 72 (69%) | 27 (47%) | 58 (72%) | 85 (62%) | ||
| Platelets (baseline) | 0.42 | 0.59 | |||||
| ≤ ULN | 28 (74%) | 73 (65%) | 43 (70%) | 58 (65%) | 101 (67%) | ||
| > ULN | 10 (26%) | 39 (35%) | 18 (30%) | 31 (35%) | 49 (33%) | ||
| Primary tumor location | 0.40 | 0.58 | |||||
| left side | 25 (74%) | 67 (64%) | 38 (69%) | 54 (64%) | 92 (66%) | ||
| right side | 9 (26%) | 38 (36%) | 17 (31%) | 30(36%) | 47(34%) | ||
CEA ≥ 20 ng/mL is suggestive of cancer and metastasis.
ctDNAf, ctDNA concentration at follow-up; ctDNAb, ctDNA concentration at baseline ULN, upper limit of normal; ECOG, eastern cooperative oncology group; CEA, carcinoembryonic antigen.
| . | ctDNAb . | ctDNAf . | . | ||||
|---|---|---|---|---|---|---|---|
| Characteristic . | negative . | positive . | P-value . | negative . | positive . | P-value . | Total . |
| n | 38 | 113 | 61 | 90 | 151 | ||
| Age | 0.13 | 0.18 | |||||
| Mean ± SD | 60.7 ± 9 | 63.8 ± 9.7 | 62.4 ± 9.5 | 63.5 ± 9.7 | 63.1 ± 9.6 | ||
| < 65 y | 23 (61%) | 51 (45%) | 34 (56%) | 40 (44%) | 74 (49%) | ||
| ≥ 65 y | 15 (39%) | 62 (55%) | 27 (44%) | 50 (56%) | 77 (51%) | ||
| Sex | 0.84 | 0.73 | |||||
| Male | 24 (63%) | 75 (66%) | 39 (64%) | 60 (67%) | 99 (66%) | ||
| Female | 14 (37%) | 38 (34%) | 22 (36%) | 30 (33%) | 52 (34%) | ||
| Performance status | 0.84 | 0.86 | |||||
| ECOG 0 | 22 (59%) | 68 (61%) | 36 (60%) | 54 (61%) | 90 (61%) | ||
| ECOG 1/2 | 15 (41%) | 43 (39%) | 24 (40%) | 34 (39%) | 58 (39%) | ||
| Type of metastasis | 1.00 | 1.00 | |||||
| synchronous | 34 (89%) | 100 (88%) | 54 (89%) | 80 (89%) | 134 (89%) | ||
| metachronous | 4 (11%) | 13 (12%) | 7 (11%) | 10 (11%) | 17 (11%) | ||
| Number of metastatic sites | 0.13 | 0.39 | |||||
| 1 | 20 (53%) | 42 (37%) | 28 (46%) | 34 (38%) | 62 (41%) | ||
| > 1 | 18 (47%) | 71 (63%) | 33 (54%) | 56 (62%) | 89 (59%) | ||
| aCEA (baseline) | 0.0021 | 0.0047 | |||||
| ≤ 20 ng/mL | 21 (62%) | 32 (31%) | 30 (53%) | 23 (28%) | 53 (38%) | ||
| > 20 ng/mL | 13 (38%) | 72 (69%) | 27 (47%) | 58 (72%) | 85 (62%) | ||
| Platelets (baseline) | 0.42 | 0.59 | |||||
| ≤ ULN | 28 (74%) | 73 (65%) | 43 (70%) | 58 (65%) | 101 (67%) | ||
| > ULN | 10 (26%) | 39 (35%) | 18 (30%) | 31 (35%) | 49 (33%) | ||
| Primary tumor location | 0.40 | 0.58 | |||||
| left side | 25 (74%) | 67 (64%) | 38 (69%) | 54 (64%) | 92 (66%) | ||
| right side | 9 (26%) | 38 (36%) | 17 (31%) | 30(36%) | 47(34%) | ||
| . | ctDNAb . | ctDNAf . | . | ||||
|---|---|---|---|---|---|---|---|
| Characteristic . | negative . | positive . | P-value . | negative . | positive . | P-value . | Total . |
| n | 38 | 113 | 61 | 90 | 151 | ||
| Age | 0.13 | 0.18 | |||||
| Mean ± SD | 60.7 ± 9 | 63.8 ± 9.7 | 62.4 ± 9.5 | 63.5 ± 9.7 | 63.1 ± 9.6 | ||
| < 65 y | 23 (61%) | 51 (45%) | 34 (56%) | 40 (44%) | 74 (49%) | ||
| ≥ 65 y | 15 (39%) | 62 (55%) | 27 (44%) | 50 (56%) | 77 (51%) | ||
| Sex | 0.84 | 0.73 | |||||
| Male | 24 (63%) | 75 (66%) | 39 (64%) | 60 (67%) | 99 (66%) | ||
| Female | 14 (37%) | 38 (34%) | 22 (36%) | 30 (33%) | 52 (34%) | ||
| Performance status | 0.84 | 0.86 | |||||
| ECOG 0 | 22 (59%) | 68 (61%) | 36 (60%) | 54 (61%) | 90 (61%) | ||
| ECOG 1/2 | 15 (41%) | 43 (39%) | 24 (40%) | 34 (39%) | 58 (39%) | ||
| Type of metastasis | 1.00 | 1.00 | |||||
| synchronous | 34 (89%) | 100 (88%) | 54 (89%) | 80 (89%) | 134 (89%) | ||
| metachronous | 4 (11%) | 13 (12%) | 7 (11%) | 10 (11%) | 17 (11%) | ||
| Number of metastatic sites | 0.13 | 0.39 | |||||
| 1 | 20 (53%) | 42 (37%) | 28 (46%) | 34 (38%) | 62 (41%) | ||
| > 1 | 18 (47%) | 71 (63%) | 33 (54%) | 56 (62%) | 89 (59%) | ||
| aCEA (baseline) | 0.0021 | 0.0047 | |||||
| ≤ 20 ng/mL | 21 (62%) | 32 (31%) | 30 (53%) | 23 (28%) | 53 (38%) | ||
| > 20 ng/mL | 13 (38%) | 72 (69%) | 27 (47%) | 58 (72%) | 85 (62%) | ||
| Platelets (baseline) | 0.42 | 0.59 | |||||
| ≤ ULN | 28 (74%) | 73 (65%) | 43 (70%) | 58 (65%) | 101 (67%) | ||
| > ULN | 10 (26%) | 39 (35%) | 18 (30%) | 31 (35%) | 49 (33%) | ||
| Primary tumor location | 0.40 | 0.58 | |||||
| left side | 25 (74%) | 67 (64%) | 38 (69%) | 54 (64%) | 92 (66%) | ||
| right side | 9 (26%) | 38 (36%) | 17 (31%) | 30(36%) | 47(34%) | ||
CEA ≥ 20 ng/mL is suggestive of cancer and metastasis.
ctDNAf, ctDNA concentration at follow-up; ctDNAb, ctDNA concentration at baseline ULN, upper limit of normal; ECOG, eastern cooperative oncology group; CEA, carcinoembryonic antigen.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
